Cargando…

APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study

RATIONALE & OBJECTIVE: Apolipoprotein L1 (APOL1) high-risk variants are associated with an increased risk for chronic kidney disease (CKD) among African Americans. Less is known regarding the risk for the development of CKD and kidney failure (end-stage kidney disease [ESKD]) among African Ameri...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Bessie A., Wilson, James G., Reiner, Alex, Kestenbaum, Bryan, Franceschini, Nora, Bansal, Nisha, Correa, Adolfo, Himmelfarb, Jonathan, Katz, Ronit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664705/
https://www.ncbi.nlm.nih.gov/pubmed/34939005
http://dx.doi.org/10.1016/j.xkme.2021.05.004
_version_ 1784613900065439744
author Young, Bessie A.
Wilson, James G.
Reiner, Alex
Kestenbaum, Bryan
Franceschini, Nora
Bansal, Nisha
Correa, Adolfo
Himmelfarb, Jonathan
Katz, Ronit
author_facet Young, Bessie A.
Wilson, James G.
Reiner, Alex
Kestenbaum, Bryan
Franceschini, Nora
Bansal, Nisha
Correa, Adolfo
Himmelfarb, Jonathan
Katz, Ronit
author_sort Young, Bessie A.
collection PubMed
description RATIONALE & OBJECTIVE: Apolipoprotein L1 (APOL1) high-risk variants are associated with an increased risk for chronic kidney disease (CKD) among African Americans. Less is known regarding the risk for the development of CKD and kidney failure (end-stage kidney disease [ESKD]) among African Americans with only 1 APOL1 risk variant or whether the risk is modified by sickle cell trait. STUDY DESIGN: The Jackson Heart Study is a community-based longitudinal cohort study. SETTING & PARTICIPANTS: Self-reported African Americans in the Jackson Heart Study (n = 5,306). EXPOSURES: APOL1 G1 and G2 genotypes and sickle cell trait. OUTCOMES: Incident CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m(2)), albuminuria (urinary albumin-creatinine ratio ≥ 30 mg/g), continuous and rapid kidney function decline (≥30% decline), and incident ESKD. ANALYTICAL APPROACH: Multivariable linear and logistic regression, and Cox proportional hazards models adjusted for age, sex, hypertension, diabetes, ancestry informative markers, and sickle cell trait. RESULTS: Of 2,300 participants, 41.3% had zero, 45.1% had 1, and 13.6% had 2 APOL1 risk variants. Sickle cell trait was present in 8.5%. Compared with participants with zero APOL1 risk variants, those with 2 alleles had an increased risk for incident albuminuria (adjusted HR [aHR], 1.88; 95% CI, 1.04 to 3.40), ESKD (aHR, 9.05; 95% CI, 1.79 to 45.85), incident CKD (aHR, 1.65; 95% CI, 1.06 to 2.57), continuous decline (β = −1.90; 95% CI, −3.35 to −0.45), and rapid kidney function decline (OR, 2.21; 95% CI, 1.22 to 4.00) after adjustment for sickle cell trait, with similar results after adjustment for ancestry informative markers. Having 1 APOL1 risk variant was not associated with CKD outcomes and there was no interaction of APOL1 with sickle cell trait. LIMITATIONS: Single-site recruitment of African American individuals with APOL1 and sickle cell trait. CONCLUSIONS: The presence of 1 APOL1 risk allele was not associated with increased risk for CKD outcomes, whereas 2 risk alleles were associated with incident albuminuria, CKD, ESKD, and rapid and continuous kidney function decline. Additional studies are needed to determine factors that might alter the risk for adverse kidney outcomes among individuals with high-risk APOL1 genotypes.
format Online
Article
Text
id pubmed-8664705
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86647052021-12-21 APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study Young, Bessie A. Wilson, James G. Reiner, Alex Kestenbaum, Bryan Franceschini, Nora Bansal, Nisha Correa, Adolfo Himmelfarb, Jonathan Katz, Ronit Kidney Med Original Research RATIONALE & OBJECTIVE: Apolipoprotein L1 (APOL1) high-risk variants are associated with an increased risk for chronic kidney disease (CKD) among African Americans. Less is known regarding the risk for the development of CKD and kidney failure (end-stage kidney disease [ESKD]) among African Americans with only 1 APOL1 risk variant or whether the risk is modified by sickle cell trait. STUDY DESIGN: The Jackson Heart Study is a community-based longitudinal cohort study. SETTING & PARTICIPANTS: Self-reported African Americans in the Jackson Heart Study (n = 5,306). EXPOSURES: APOL1 G1 and G2 genotypes and sickle cell trait. OUTCOMES: Incident CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m(2)), albuminuria (urinary albumin-creatinine ratio ≥ 30 mg/g), continuous and rapid kidney function decline (≥30% decline), and incident ESKD. ANALYTICAL APPROACH: Multivariable linear and logistic regression, and Cox proportional hazards models adjusted for age, sex, hypertension, diabetes, ancestry informative markers, and sickle cell trait. RESULTS: Of 2,300 participants, 41.3% had zero, 45.1% had 1, and 13.6% had 2 APOL1 risk variants. Sickle cell trait was present in 8.5%. Compared with participants with zero APOL1 risk variants, those with 2 alleles had an increased risk for incident albuminuria (adjusted HR [aHR], 1.88; 95% CI, 1.04 to 3.40), ESKD (aHR, 9.05; 95% CI, 1.79 to 45.85), incident CKD (aHR, 1.65; 95% CI, 1.06 to 2.57), continuous decline (β = −1.90; 95% CI, −3.35 to −0.45), and rapid kidney function decline (OR, 2.21; 95% CI, 1.22 to 4.00) after adjustment for sickle cell trait, with similar results after adjustment for ancestry informative markers. Having 1 APOL1 risk variant was not associated with CKD outcomes and there was no interaction of APOL1 with sickle cell trait. LIMITATIONS: Single-site recruitment of African American individuals with APOL1 and sickle cell trait. CONCLUSIONS: The presence of 1 APOL1 risk allele was not associated with increased risk for CKD outcomes, whereas 2 risk alleles were associated with incident albuminuria, CKD, ESKD, and rapid and continuous kidney function decline. Additional studies are needed to determine factors that might alter the risk for adverse kidney outcomes among individuals with high-risk APOL1 genotypes. Elsevier 2021-07-15 /pmc/articles/PMC8664705/ /pubmed/34939005 http://dx.doi.org/10.1016/j.xkme.2021.05.004 Text en © 2021 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Young, Bessie A.
Wilson, James G.
Reiner, Alex
Kestenbaum, Bryan
Franceschini, Nora
Bansal, Nisha
Correa, Adolfo
Himmelfarb, Jonathan
Katz, Ronit
APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study
title APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study
title_full APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study
title_fullStr APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study
title_full_unstemmed APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study
title_short APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study
title_sort apol1, sickle cell trait, and ckd in the jackson heart study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664705/
https://www.ncbi.nlm.nih.gov/pubmed/34939005
http://dx.doi.org/10.1016/j.xkme.2021.05.004
work_keys_str_mv AT youngbessiea apol1sicklecelltraitandckdinthejacksonheartstudy
AT wilsonjamesg apol1sicklecelltraitandckdinthejacksonheartstudy
AT reineralex apol1sicklecelltraitandckdinthejacksonheartstudy
AT kestenbaumbryan apol1sicklecelltraitandckdinthejacksonheartstudy
AT franceschininora apol1sicklecelltraitandckdinthejacksonheartstudy
AT bansalnisha apol1sicklecelltraitandckdinthejacksonheartstudy
AT correaadolfo apol1sicklecelltraitandckdinthejacksonheartstudy
AT himmelfarbjonathan apol1sicklecelltraitandckdinthejacksonheartstudy
AT katzronit apol1sicklecelltraitandckdinthejacksonheartstudy